Funding for this research was provided by:
Health Technology Assessment Programme (96/20/99)
Cancer Research UK (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, and C18281/A24432)
Received: 28 February 2020
Accepted: 9 August 2020
First Online: 7 October 2020
Ethics approval and consent to participate
: The UK’s East Midlands (formerly Trent) Multicenter Research Ethics Committee (reference number 01/4/025) gave ethical approval for the ProtecT trial. The study was performed in accordance with the declaration of Helsinki. All participants provided their informed consent before participating in the study. The authors were part of the ProtecT trial team and therefore additional administrative permission was not required to access raw data from the trial.
: Not applicable.
: SS, KG, SN, CM, JAL, FCH, DN and JLD had financial support from NIHR HTA and RMM and ET from CRUK for the submitted work; All other authors declare no conflict of interest.